- Activity pressure is positive on the latest completed week.
- Next-week expectancy is positive at 55.60% based on similar historical setup states.
SNY
NASDAQ
Week ended 07 Aug 2026
Weekly Investor Report
Sanofi ADR · Healthcare · Drug Manufacturers - General
Latest close
43.46 USD
0.9%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -0.9% below the Trend Line and sits at 28.5% of its 52-week range. The latest completed week returned 0.9%, after a -0.1% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is bearish with 39/100 conviction, while the latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.
Setup score
44
out of 100
Latest Close
43.46 USD
7 Aug 2026
1W Return
0.9%
latest completed week
4W Return
-0.1%
short-term follow-through
12W Return
1.8%
quarterly tape
Trend Breadth
5.8%
3 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
0.9%
Latest completed week; four-week move -0.1%.
Indicator stack
3/96
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Positive 55.60%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Bearish
39/100 conviction; expected move 3.8%.
News sentiment
50/100
50 relevant articles in the latest sentiment read.
Event risk
30 Jul
Latest stored earnings date was 30 Jul 2026.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -0.9% below the Trend Line and sits at 28.5% of its 52-week range. The latest completed week returned 0.9%, after a -0.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1912-week average 0.11
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.19Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -0.1% over four weeks, 1.8% over 12 weeks, and -2.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year3
Trend breadth5.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.34Latest activity-pressure read.
Pressure change501.6%Four-week change in activity pressure.
Leadership-15.89Latest relative-leadership reading.
RS change10.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 30 Jun 2026
Field coverage 97%
Model confidence 97%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength77/100Blend of value, momentum, and quality. Underlying universe rank 24; rank 1 is best.
Value72/100Relative valuation strength. Underlying universe rank 29; rank 1 is best.
Quality93/100Profitability and accounting quality. Underlying universe rank 8; rank 1 is best.
Momentum16/100Medium-term price momentum. Underlying universe rank 85; rank 1 is best.
Growth7/100Revenue and earnings growth. Underlying universe rank 94; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework75/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 26.7x Price divided by trailing earnings.
- Price / sales
- 2.2x Market value relative to trailing revenue.
- EV / EBITDA
- 9.9x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 14.0% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 73.0% Gross profit retained from each unit of revenue.
- Operating margin
- 18.2% Operating profit retained from revenue.
- Free-cash-flow margin
- 35.2% Free cash flow generated from revenue.
- Return on invested capital
- 7.9% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 13.4% Latest one-year revenue growth.
- EPS growth
- -56.6% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 5.6% Cash dividends relative to market value.
- Buyback yield
- 4.6% Net share repurchases relative to market value.
- Shareholder yield
- 10.2% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningBearish
SNY shows bearish options pressure with a 39/100 conviction score, put-call volume ratio of 1.64, expected move of 3.8%, and Sharemaestro trend signal inactive.
Conviction39/100
Expected move3.8%
Put/call volume1.64
Insider activity2 / 1
2 acquisitions and 1 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment50/100
Weighted news tone is neutral across 50 relevant articles.
18 positive · 18 neutral · 14 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings30 JulLatest stored earnings date was 30 Jul 2026.
Options expected move3.8%Nearest-chain priced movement where available.
52-week drawdown-12.9%Distance below the 52-week high.
13-week volatility2.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+4.9%Week of 27 Mar.
Worst week-8.4%Week of 6 Mar.
Latest week+0.9%Week of 7 Aug.
Shape of recent returns
Strong gains2
Modest gains11
Flat weeks0
Modest losses11
Sharp losses2
Recent vol2.3%13-week weekly-return volatility.
Base vol3.5%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew2.8% / -2.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank63 / 100
Group average2.6%
Trend breadth54.0%
Trend54.0%active weekly trend signals
MD77.0%positive activity pressure
RS44.0%positive relative leadership
Four-week leaders
IndustryUS Drug Manufacturers - General
4-week rank12 / 20
Group average-1.3%
Trend breadth50.0%
Trend50.0%active weekly trend signals
MD70.0%positive activity pressure
RS35.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape42/100
Trend, activity pressure, participation, and risk combine to a 42/100 tape read.
Indicator analysis31/100Latest 12-week confirmation: trend 0/12, activity pressure 11/12, relative leadership 0/12.
Activity pressure 0.19; No reversal markers Next-Week ExpectancyPositive 55.60%Next-week expectancy is positive with a 55.60% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors66/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 12 SVQF75/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 178.0 of 718 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options57/100SNY shows bearish options pressure with a 39/100 conviction score, put-call volume ratio of 1.64, expected move of 3.8%, and Sharemaestro trend signal inactive.
Bearish · Put-side pressure · Expected move 3.8% Sentiment50/100Weighted news tone is neutral across 50 relevant articles.
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments Insiders2 / 12 acquisitions and 1 disposals in the latest 180-day insider tape.
Earnings30 JulLatest stored earnings date was 30 Jul 2026.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 43.46 USD | 0.9% | 43.85 USD | 45.44 USD | 0.34 | -15.89 | 14.3M | Off |
| 31 Jul 2026 | 43.08 USD | -0.6% | 43.95 USD | 45.46 USD | 0.20 | -12.80 | 22.5M | Off |
| 24 Jul 2026 | 43.35 USD | -2.9% | 44.04 USD | 45.47 USD | 0.04 | -12.18 | 17.1M | Off |
| 17 Jul 2026 | 44.66 USD | 2.7% | 44.12 USD | 45.49 USD | 0.17 | -11.47 | 13.5M | Off |
| 10 Jul 2026 | 43.50 USD | 0.8% | 44.15 USD | 45.51 USD | 0.06 | -17.74 | 16.2M | Off |
| 3 Jul 2026 | 43.16 USD | 0.5% | 44.24 USD | 45.52 USD | 0.28 | -17.42 | 13.7M | Off |
| 26 Jun 2026 | 42.95 USD | 1.3% | 44.37 USD | 45.53 USD | 0.48 | -17.59 | 35.8M | Off |
| 19 Jun 2026 | 42.38 USD | -4.2% | 44.51 USD | 45.56 USD | 0.32 | -22.78 | 15.9M | Off |
| 12 Jun 2026 | 44.25 USD | -1.7% | 44.66 USD | 45.58 USD | 0.31 | -17.84 | 13.6M | Off |
| 5 Jun 2026 | 45.02 USD | 3.1% | 44.83 USD | 45.59 USD | 0.11 | -15.10 | 12.0M | Off |
| 29 May 2026 | 43.67 USD | -1.4% | 44.90 USD | 45.59 USD | -0.00 | -21.89 | 9.4M | Off |
| 22 May 2026 | 44.29 USD | 3.7% | 45.04 USD | 45.59 USD | 0.02 | -19.13 | 12.4M | Off |
| 15 May 2026 | 42.69 USD | -1.4% | 45.20 USD | 45.59 USD | 0.04 | -21.80 | 16.9M | Off |
| 8 May 2026 | 43.31 USD | -0.8% | 45.37 USD | 45.61 USD | 0.18 | -21.59 | 11.2M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.